temas especiales
Glucosamina
Referencias
1.Liu L, Liu Y, Shin HD, et al: Microbial production of glucosamine and N-acetylglucosamine: advances and perspectives.Appl Microbiol Biotechnol97(14):6149-6158, 2013. doi: 10.1007/s00253-013-4995-6 2.Wu D, Huang Y, Gu Y, et al: Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials.Int J Clin Pract67(6):585-594, 2013. doi: 10.1111/ijcp.12115 3.Eriksen P, Bartels EM, Altman RD, et al: Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials.Arthritis Care Res (Hoboken)66(12):1844-1855, 2014. doi: 10.1002/acr.22376 4.Clegg DO, Reda DJ, Harris CL, et al: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.N Engl J Med354(8):795-808, 2006. doi: 10.1056/NEJMoa052771 5.Hochberg MC, Martel-Pelletier J, Monfort J, et al: Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versuscelecoxib.Ann Rheum Dis75:37-44, 2016. doi:10.1136/annrheumdis-2014-206792 6.Kolasinski SL, Neogi T, Hochberg MC, et al: 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee.Arthritis Care Res (Hoboken)72(2):149‐162. doi:10.1002/acr.24131 7.Bruyère O, Honvo G, Veronese N, et al: An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).Semin Arthritis Rheum49(3):337-350, 2019. doi:10.1016/j.semarthrit.2019.04.008 8.Cerda C, Bruguera M, Parés A: Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease.World J Gastroenterol19(32):5381-5384, 2013. doi: 10.3748/wjg.v19.i32.5381 